Clovis Oncology, Inc. prices $75 million public offering of common stock.
On April 3, Willkie client Clovis Oncology, Inc. announced that it has priced its underwritten public offering of 3,750,000 shares of its common stock at $20.00 per share. The offering is expected to close on April 10, 2012. In November 2011, Willkie assisted the company in its $130 million initial public offering of 10 million shares. Founded in 2009, Boulder, Colorado-based Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The deal was handled by Peter Jakes, William Gump, Thomas Mark, Martin Miller and Amanda Burke.